Subclinical tumor lysis-like syndrome during treatment of visceral leishmaniasis with low-dose intermittent liposomal amphotericin B

• Authors: Sarah Georgiadou , Dimitrios Kontoyiannis , Nikolaos Sipsas
• Languages of publication: EN

Abstracts

EN

We retrospectively evaluated the rate of renal dysfunction during treatment with liposomal amphotericin B (L-AmB) (3–4 mg/kg, for 7–10 days) in nine consecutive patients with visceral leishmaniasis (VL). During the first week of treatment, 5 patients (56%) experienced transient deterioration of renal function, with a rise in serum creatinine to 1.27–2.44 times the baseline level, and a parallel elevation of uric acid levels without other metabolic or electrolyte disturbances. Serum renal function parameters were restored to normal levels after the completion of therapy, on day 21. These 5 patients had presented with prolonged fever and/or significant spleen enlargement, reflecting high parasite load. This observation suggests that treatment of VL with intermittent L-AmB causes a subclinical tumor lysis-like syndrome, especially in patients with high parasite load.

Keywords

EN

Visceral leishmaniasis; Liposomal amphotericin B; Renal function; Uric acid; Tumor lysis syndrome

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2012
• Volume: 7
• Issue: 3
• Pages: 305-309

Dates

published

1 - 6 - 2012

online

29 - 3 - 2012

Contributors

author

Sarah Georgiadou

• Infectious Diseases Unit, Pathophysiology Department, Laikon General Hospital and Medical School, National and Kapodistrian University of Athens, 75 Mikras Asias Str, 11527, Athens, Greece

author

Dimitrios Kontoyiannis

• Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, Texas, USA

author

Nikolaos Sipsas

• Infectious Diseases Unit, Pathophysiology Department, Laikon General Hospital and Medical School, National and Kapodistrian University of Athens, 75 Mikras Asias Str, 11527, Athens, Greece

References

• [1] Herwaldt BL. Leishmaniasis. Lancet 1999, 354, 1191–1199 http://dx.doi.org/10.1016/S0140-6736(98)10178-2[Crossref]
• [2] Daher EF, Evangelista LF, Silva Júnior GB, Lima RS, Aragão EB, Arruda GA, et al. Clinical presentation and renal evaluation of human visceral leishmaniasis (kala-azar): a retrospective study of 57 patients in Brazil. Braz J Infect Dis 2008, 12, 329–332 http://dx.doi.org/10.1590/S1413-86702008000400015[Crossref]
• [3] Clevenbergh P, Okome MN, Benoit S, Bendini JC, De Salvador F, Elbeze M, et al. Acute renal failure as initial presentation of visceral leishmaniasis in an HIV-1-infected patient. Scand J Infect Dis 2002, 34, 546–547 http://dx.doi.org/10.1080/003655402320208857[Crossref]
• [4] Beltrame A, Arzese A, Camporese A, Rorato G, Crapis M, Tarabini-Castellani G, et al. Acute renal failure due to visceral leishmaniasis by Leishmania infantum successfully treated with a single high dose of liposomal amphotericin B. J Travel Med. 2008,15, 358–360 http://dx.doi.org/10.1111/j.1708-8305.2008.00220.x[Crossref][WoS]
• [5] Efstratiadis G, Boura E, Giamalis P, Mandala E, Leontsini M, Tsiaousis G, et al. Renal involvement in a patient with visceral leishmaniasis. Nephrol Dial Transplant 2006, 21, 235–236 http://dx.doi.org/10.1093/ndt/gfi157[Crossref]
• [6] Navarro M, Bonet J, Bonal J, Romero R. Secondary amyloidosis with irreversible acute renal failure caused by visceral leishmaniasis in a patient with AIDS. Nefrologia. 2006, 26, 745–746 (in Spanish)
• [7] Lima Verde FA, Lima Verde FA, Lima Verde IA, Silva Junior GB, Daher EF, Lima Verde EM. Evaluation of renal function in human visceral leishmaniasis (kala-azar): a prospective study on 50 patients from Brazil. J Nephrol. 2007, 20, 430–436
• [8] Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999, 340, 764–771 http://dx.doi.org/10.1056/NEJM199903113401004[Crossref]
• [9] Safdar A, Ma J, Saliba F, Dupont B, Wingard JR, Hachem RY, et al. Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis. Medicine (Baltimore) 2010, 89, 236–244 http://dx.doi.org/10.1097/MD.0b013e3181e9441b[Crossref][WoS]
• [10] Ullmann AJ, Sanz MA, Tramarin A, Barnes RA, Wu W, Gerlach BA, et al. Longitudinal Evaluation of Antifungal Drugs (LEAD I) Investigators. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis 2006, 43, 29–38 [Crossref]
• [11] Meyerhoff A. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis. 1999, 28, 42–48 http://dx.doi.org/10.1086/515085[Crossref]
• [12] Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN, et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis. 2006, 43, 917–924 http://dx.doi.org/10.1086/507530[Crossref]
• [13] Davidson RN, di Martino L, Gradoni L, Giacchino R, Gaeta GB, Pempinello R, et al. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis 1996, 22, 938–943 http://dx.doi.org/10.1093/clinids/22.6.938[Crossref]
• [14] Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, et al. AmBiLoad Trial Study Group. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007, 44, 1289–1297 http://dx.doi.org/10.1086/514341[WoS][Crossref]
• [15] Liberopoulos E, Alexandridis G, Elisaf M. A tumor lysis-like syndrome during therapy of visceral leishmaniasis. Ann Clin Lab Sci 2002, 32, 419–421
• [16] Liberopoulos EN, Kei AA, Elisaf MS. Lysis syn-syndrome during therapy of visceral leishmaniasis. Infection. 2011 Oct 18 [WoS]
• [17] Cairo MS, Bishop M. Tumor lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004, 127, 3–11 http://dx.doi.org/10.1111/j.1365-2141.2004.05094.x[Crossref]
• [18] Mukherjee AK, Gupta G, Bhattacharjee S, Guha SK, Majumder S, Adhikari A, et al. Amphotericin B regulates the host immune response in visceral leishmaniasis: reciprocal regulation of protein kinase C isoforms. J Infect. 2010, 61, 173–184 http://dx.doi.org/10.1016/j.jinf.2010.05.003[Crossref][WoS]
• [19] Shaha C. Apoptosis in Leishmania species and its relevance to disease pathogenesis. Indian J Med Res. 2006, 123, 233–244
• [20] Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis 2004, 38, 377–383 http://dx.doi.org/10.1086/380971[Crossref]
• [21] Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ 2001, 323, 419–422 http://dx.doi.org/10.1136/bmj.323.7310.419[Crossref]
• [22] Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis 2003, 37, 800–804 http://dx.doi.org/10.1086/377542[Crossref]
• [23] Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 2010, 362, 5 http://dx.doi.org/10.1056/NEJMoa0903627[Crossref]

Identifiers

DOI

10.2478/s11536-011-0147-5